Research and Markets: U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/649767/u_s_rheumatoid_ar) has announced the addition of Frost & Sullivan's new report "U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments" to their offering.

This research service covers the U.S. rheumatoid arthritis (RA) market from 2007 to 2017, with 2010 as the base year. Included in this research service are products currently in the market, products in development, and patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented to overcome listed industry challenges. This research service does not include market revenue forecasts for DMARDs. This research service highlights product forecasts for biologic products as well as small molecules near launch.

The market is segmented into the following sections by drug class:

  • Disease-modifying antirheumatic drugs (DMARDs)
  • Anti-tumor necrosis factor alpha (anti-TNF-alphas)
  • Other biologics
  • Small molecules

This research service does not include market revenue forecasts for DMARDs. This research service highlights product forecasts for DMARDs, anti-TNF-alphas, and other biologic products as well as small molecules near launch.

Methodology:

The research for this analysis was conducted using an assortment of primary and secondary information sources.

Primary interviews were conducted with industry participants in positions such as director of investor relations, vice president of corporate communications, sales and marketing, medical information, and clinical trial staff.

Secondary research included data from various sources to gain insight into RA treatment options, statistics, and other associated medical factors. Statistics were gathered from various sources such as U.S. Securities and Exchange Commission (SEC) filings, the Center for Disease Control and Prevention (CDC), World Population Data Sheets, the National Institutes of Health (NIH), the National Center for Health Statistics, as well as scientific journals and industry-related articles.

Key Topics Covered:

Scope

Methodology

Market Introduction

Patient Outlook

Industry Challenges

Current Treatments

Key Trends

Market Drivers and Restraints

Market Analysis and Forecasts

Product Forecasts

Competitive Analysis

Pipeline Analysis

Strategic Recommendations

Conclusions

For more information visit http://www.researchandmarkets.com/research/649767/u_s_rheumatoid_ar



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.